Results 131 to 140 of about 896,459 (312)
Stemness properties, including quiescence, self‐renewal, and chemoresistance, are closely associated with leukemia relapse. Here, we demonstrate that DNA damage‐inducible transcript 4 (DDIT4) is induced in the hypoxic bone marrow niche and is essential for maintaining the stemness of AML1‐ETO9a leukemia cells.
Yishuang Li+12 more
wiley +1 more source
Fluorescence studies of drug and cation interactions with microsomal membranes [PDF]
Hilary C. Hawkins, Robert B. Freedman
openalex +1 more source
Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi+12 more
wiley +1 more source
Pharmacology and relevant drug interactions of metamizole. [PDF]
Brinkman DJ+3 more
europepmc +1 more source
Diflunisal: a review of pharmacokinetic and pharmacodynamic properties, drug interactions, and special tolerability studies in humans. [PDF]
KF Tempero, VJ Cirillo, S L Steelman
openalex +1 more source
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh+5 more
wiley +1 more source
The Effect of Drug-Drug Interactions on the Pharmacokinetics of Isavuconazole: A Comprehensive Review. [PDF]
Sang Y, Xu Q, Gao A, Zhao Q.
europepmc +1 more source
Interaction of Diazepam with the Muscle-relaxant Drugs [PDF]
S. A. Feldman, Barbara Crawley
openalex +1 more source
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha+10 more
wiley +1 more source